Monthly Archives: April 2020

Blueprint Medicines Presents Cost of Testing Poster

Blueprint Medicines presented a poster titled “The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors” at the annual meeting of the AMCP.

By |2020-04-30T14:50:52-04:00April 30th, 2020|Mutational Testing, News, Patient Support|

Science Forum Convened to Better Understand the State of GIST Research

As research regarding GIST and other relevant topics is extensive and dynamic, consensus among the Real World Evidence Team was that it would be a good idea to convene a group tasked with monitoring and assessing this research. Recently the LRG held its inaugural virtual meeting of the newly formed LRG Science Forum.

By |2020-04-28T15:55:34-04:00April 28th, 2020|News, Newsletter, Research|

Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial

Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor in patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST).

By |2020-04-28T13:52:38-04:00April 28th, 2020|News|
Go to Top